NYR's Principal Activity is the development of therapeutic treatments for cardiovascular, neurological and inflammatory/autoimmune diseases, testing and optimization of novel drug candidates while building on the Company's patent portfolio.
|Bid / Ask||-|
|Volume (4w avg)|
|vs Sector (1yr)||+120.78%|
|vs ASX 200 (1yr)||+83.38%|
|ASX Rank||1,490 of 2,237|
|Sector Rank||135 of 177|
Nyrada Inc (NYR) is a preclinical stage, drug development company. The Company specialises in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases. It focuses on areas of substantial unmet clinical need and has identified drug candidates with therapeutic and commercial potential, where few if any, effective or well-tolerated therapies exist. It currently has three wholly-owned drug programs:
No incorporation details available.
|No dividends paid.|
See Upcoming Dividends for all ASX companies.
|Dr Ian Edward Dixon||Founder,Non-Executive Director||Sep 2020||
Dr Ian Edward Dixon
Dr Dixon has more than 20 years' experience in the Australian sector. Ian is a co-inventor of the technology behind its Cholesterol Lowering Program, giving him experience in the development of PCSK9 inhibitors. Dr Dixon is also Chairman and founder of Altnia Group, a privately held Australian biotechnology incubator and life sciences R&D company. Currently Founder and Managing Director of exosome medicine company, Exopharm (ASX: EX1), Dr Dixon also serves as a part-time executive director of Medigard Ltd (ASX: MGZ). In addition, Dr Dixon co-founded Cynata Inc. - now a subsidiary of Australian listed biotechnology company, Cynata Therapeutics Ltd (ASX: CYP). Until recently he was a non-executive director of Noxopharm Ltd (ASX: NOX). Dr Dixon was a director of Cell Therapies Pty Ltd.
|Mr Christopher Cox||Non-Executive Director||Nov 2019||
Mr Christopher Cox
Mr Cox has been a partner at Cadwalader, Wickersham & Taft LLP in New York since January 2012. Previously the Chairman of Cadwalader's Department and a Member of its Management Committee, he advises clients on a of corporate and financial matters, including mergers and acquisitions and restructurings, spin-offs, joint ventures, IP monetizations and other financing transactions. From February 2016 to March 2019, he was seconded to The Medicines Company, a biopharmaceutical company, where he served as Executive Vice President and Chief Corporate Development Officer and was in charge for business development and strategy. Prior to January 2012, he was a partner at Cahill Gordon & Reindel LLP in New York. He also serves as the Chief Executive Officer of Symphony Capital Holdings, LLC, a investment holding company with interests in biotechnology, network security and entertainment. He was also a Member of the Missouri Law Review.
|Mr John Alexander Moore||Non-Executive Chairman,Non-Executive Director||Jun 2019||
Mr John Alexander Moore
Non-Executive Chairman,Non-Executive Director
Mr Moore currently serves as Chairman of Trialogics a clinical trial informatics business. He was CEO of Acorn Energy from 2006 to 2015. In 2002 he was a partner and CEO of Edson Moore Healthcare Ventures. He is a director of Scientific Industries, a producer of laboratory instruments for the life sciences industry.
|Mr Ruediger Weseloh||Non-Executive Director||Jun 2019||
Mr Ruediger Weseloh
Mr Weseloh is a Director of Business Development at Merck KgaA, Darmstadt, Germany, where, in 14 years of doing BD, he has led it's transactions for the pharmaceutical division, doing deals across the drug development value chain in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before Merck KgaA, he spent 5 years as a Biotech/Pharma Equity Analyst, at Gontard & Metallbank, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as 3 years as a Postdoc at the Max-Planck-Institute for Medicine in Goettingen. He also serves on the Supervisory Board of Cytotools AG, Freiburg, Germany.
|Mr Marcus Frampton||Non-Executive Director||Jun 2019||
Mr Marcus Frampton
Mr Frampton currently serves as the Chief Investment Officer of the Alaska Permanent Fund Corporation (APFC). He manages the investment team at APFC and leads all investment decisions related to the APFC's investment portfolio within the guidelines set up by APFC's Board of Trustees. Prior, he held positions ranging from Investment Banking Analyst & Associate at Lehman Brothers (2002-2005), to equity investing at PCG Capital Partners (2005-2010), and acted as an executive of a equity-backed portfolio company at LPL Financial (2010-2012). He is also a shareholder and sits on the board of directors of Scientific Industries, Inc., a manufacturer of laboratory equipment and the owner of intellectual property related to bioprocessing systems.
|Mr Peter Ashley Marks||Non-Executive Director||Aug 2017||
Mr Peter Ashley Marks
Mr Marks has over 30 years experience in corporate advisory, investment banking.
|Mr David Franks||Company Secretary||N/A|
|Mr James Bonnar||Chief Executive Officer||N/A|
NYR directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
|02/03/21||John Moore||Buy||+19,000||$0.35||$6,650||On-market trade|
|02/03/21||John Moore||Buy||+500||$0.204||$102||As advised by the company|
|23/02/21||Marcus Frampton||Buy||+25,000||$0.357||$8,925||On-market trade|
|18/01/21||Ian Dixon||Issued||1,800,000||$0.40||$720,000||Director remuneration|
|25/11/20||John Moore||Buy||+32,000||$0.206||$6,600||On-market trade|
|24/11/20||Marcus Frampton||Buy||+35,000||$0.21||$7,350||On-market trade|
|10/09/20||John Moore||Buy||+32,500||$0.21||$6,825||On-market trade|
|23/04/20||John Moore||Buy||+35,000||$0.168||$5,882||On-market trade|
The current holdings of NYR directors.
|Director||Last Notice||Direct Shares||Indirect Shares||Options||Convertibles|
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
|Name||Last Notice||Total Shares||Shares Held (%)|
|Altnia Holdings Pty Ltd||30/03/2021||9,921,725||7.16|
12 month transaction history compiled from ASX announcements.
No buy transactions reported by Substantial Shareholders in the past 12 months.
12 month transaction history compiled from ASX announcements.
|Date||Name||Sold||Previous %||New %|
|06-07-20||Goodridge Nominees Pty Ltd||400,000||5.68||5.32|
|06-07-20||Goodridge Foundation Pty Ltd||6,212,416||5.68||--|
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.